Table 3.
Overlap in preclinical AD classification based on CSF and imaging biomarkers
| CSF biomarkers | |||||
|---|---|---|---|---|---|
| Normal N=127 | Stage 1N=26 | Stage 2+N=19 | SNAP N=40 | ||
| Imaging biomarkers | Normal | 79 (62%) | 10 (39%) | 2 (11%) | 23 (58%) |
| Stage 1 | 9 (7%) | 11 (42%) | 14 (74%) | 8 (20%) | |
| Stage 2+ | 5 (4%) | 5 (19%) | 3 (16%) | 3 (8%) | |
| SNAP | 34 (27%) | - | - | 6 (15%) | |
Results are number (%) of subjects in the classification groups based on CSF classification. CSF=cerebrospinal fluid; SNAP=suspected non-Alzheimer pathophysiology.